Azafaros
June 22, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
Azafaros is a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms. It is a clinical-stage company, founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC, and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by a syndicate of leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Company HQ City:
Basel
Company HQ State:
Basel-Stadt
Company HQ Country:
Switzerland
Year Founded:
2018
Lead Product in Development:
Nizubaglustat for GM1/GM2 gangliosidosis and Niemann-Pick disease Type C
CEO
Stefano Portolano
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
End 2027
What is your next catalyst (value inflection) update?
Ph3 read out
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}